Evidence mapPaperPMID 42437110Full record

ArticleOphthalmology science2026

Early Prediction of Diabetic Macular Edema via Machine Learning Survival Analysis on Checkup Data.

Yusuke Kashiwagi, Katsuyuki Chida, Ayaka Hananoe, Ryoichi Ishibashi, Masaya Koshizaka, Yoshiro Maezawa, Yosuke Inaba, Yoko Takatsuna, Tomoaki Tatsumi, Hiroko Inoue and 6 more

Abstract read
In one paragraph

Article in Ophthalmology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Yusuke KashiwagiDepartment of Artificial Intelligence Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan.
Katsuyuki ChidaDepartment of Artificial Intelligence Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan.
Ayaka HananoePredictive Medicine Special Project (PMSP), RIKEN Center for Integrative Medical Sciences (IMS), RIKEN, Kanagawa, Japan.
Ryoichi IshibashiDivision of Diabetes, Endocrinology and Metabolism, Department of Medicine, Kimitsu Chuo Hospital, Kisarazu, Japan.
Masaya KoshizakaDepartment of Endocrinology, Hematology, and Gerontology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Yoshiro MaezawaDepartment of Endocrinology, Hematology, and Gerontology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Yosuke InabaClinical Research Center, Chiba University Hospital, Chiba, Japan.
Yoko TakatsunaDepartment of Ophthalmology, Chiba Rosai Hospital, Ichihara, Japan.
Tomoaki TatsumiDepartment of Ophthalmology and Vision Science, Graduate School of Medicine, Chiba University, Chiba, Japan.
Hiroko InoueDepartment of Nephrology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Hanae WakabayashiDepartment of Nephrology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Tetsuo IshikawaDepartment of Artificial Intelligence Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan.
Akiko HanaiDepartment of Artificial Intelligence Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan.
Koutaro YokoteDepartment of Endocrinology, Hematology, and Gerontology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Katsuhiko AsanumaDepartment of Nephrology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Eiryo KawakamiDepartment of Artificial Intelligence Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To predict the risk of diabetic macular edema (DME) onset and to identify features of the risk subgroups. Design: Population-based observational study with a case-control design. Subjects and Controls: Health checkup and diagnosis data from the JMDC claims database (January 2005-July 2020), one of the largest Japanese epidemiological databases, were used. From 272 337 individuals diagnosed with type 2 diabetes (International Classification of Diseases, 10th Revision E11), we analyzed 2368 pairs of DME and non-DME individuals, which matched 1:1 by the balancing score calculated from regression analysis of DME with sex, age, months of observation, number of checkups, duration of diabetes, and months until the first checkup. Methods: We employed a multivariate Cox proportional hazards model, regularized Cox models, and a random survival forest (RSF). These models were trained via ID-level bootstrap resampling using 43 health checkup variables (missing ratio <50%) and 404 high-incidence diseases within 6 months, along with age, sex, and duration of diabetes mellitus, to assess DME risk. Temporal changes in RSF-predicted risk scores were analyzed using nonlinear modeling techniques. Main Outcome Measures: Concordance index (C-index), integrated Brier score (IBS), and cumulative/dynamic mean area under the receiver operating characteristic curve (AUC). Results: Thirteen checkup items and 44 disease history variables were significantly associated with the onset of DME. The RSF identified 43.8% of DME cases >5 years prior to onset, with a specificity of 85.5%. The RSF achieved median C-index, IBS, and mean AUC values of 0.694 (95% confidence interval, 0.688-0.697), 0.181 (0.179-0.184), and 0.750 (0.739-0.756), respectively, outperforming both multivariate and univariate Cox models. Three distinct DME risk subgroups were suggested by temporal changes in the RSF-predicted risk score. Predictors of DME onset varied markedly among these subgroups. In the explicit high-risk subgroup, urinary protein and urinary sugar were highly important, and liver function-related blood tests, such as alanine transaminase and γ-gultamyltransferase, were also ranked high in variable importance metrics. Anemia-related laboratory tests were associated with DME development only in this subgroup. Conclusions: Random survival forest demonstrated superior performance in relative risk prediction of DME using health checkup data. External validation remains an essential prerequisite before any clinical application. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Indexed as

Claims dataDiabetic macular edemaHealth checkupsMachine learningSurvival analysis

Identifiers

PMID42437110
PMCPMC13355755

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.